Investigational New Drugs
Công bố khoa học tiêu biểu
* Dữ liệu chỉ mang tính chất tham khảo
Sắp xếp:
An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action
Investigational New Drugs - Tập 15 - Trang 49-59 - 1997
Angiogenesis is a biologic process whereby endothelial cells divide and migrate
to form new blood vessels. This process is required in physiological conditions,
but is also a necessary requirement for solid tumors to grow and metastasize.
Over the last several years, the growth factors that have both a positive and
negative influence on tumor angiogenesis have been delineated. Interfering with
tum...
New microtubular agents in pediatric oncology
Investigational New Drugs - Tập 14 - Trang 49-54 - 1996
The taxanes are a new group of anticancer agents with a novel mechanism of
action. They promote microtubule assembly and stabilize the microtubules.
Paclitaxel (Taxol), the first agent in this group in clinical trials was
isolated from the Pacific yew, Taxus brevifolia in 1971. Both in preclinical and
clinical studies, paclitaxel and its semisynthetic analog docetaxel exhibit
significant antitumor...
Prospective study of left ventricular function using radionuclide scans in patients receiving mitoxantrone
Investigational New Drugs - Tập 1 - Trang 341-347 - 1983
A prospective Phase II study to evaluate the effects of mitoxantrone on left
ventricular ejection fraction (LVEF) has been carried out in patients treated
with 12 mg/m2 every three weeks. Gated radionuclide cardiac blood pool imaging
with assessment of LVEF and wall motion prior to and during graded exercise was
performed before the first and every other mitoxantrone course. Ten patients had
eithe...
Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells
Investigational New Drugs - Tập 41 - Trang 541-550 - 2023
TP53 (p53) and MYC are amongst the most frequently altered genes in cancer. Both
are thus attractive targets for new anticancer therapies. Historically, however,
both genes have proved challenging to target and currently there is no approved
therapy against either. The aim of this study was to investigate the effect of
the mutant p53 reactivating drug, COTI-2 on MYC. Total MYC, pSer62 MYC and
pThr...
Inhibition of Angiogenesis: Treatment Options for Patients with Metastatic Prostate Cancer
Investigational New Drugs - Tập 20 - Trang 183-194 - 2002
Prostate cancer is the most frequentlydiagnosed malignancy and the second
mostcommon cause of cancer-related death in menin the United States.
Unfortunately, atthe current time, no curative treatmentsare available for
metastatic prostatecancer. As is the case for most solidtumors, the recruitment
of blood vessels(angiogenesis) is key for the progressionand metastasis of
prostate cancer. Inhibition...
Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer
Investigational New Drugs - Tập 8 - Trang 283-287 - 1990
We have carried out a phase II study of intravenous menogaril given every four
weeks in a group of patients with breast cancer who had received no prior
chemotherapy for metastatic disease. Myelosuppression, nausea and vomiting and
local reactions were seen frequently. Six partial responses (median duration 154
days) were seen in 24 eligible patients. We conclude menogaril is active in
breast canc...
Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-iminodoxorubicin (GPX-150), on human topoisomerase IIβ activity and cardiac function in a chronic rabbit model
Investigational New Drugs - Tập 34 - Trang 693-700 - 2016
Purpose A novel doxorubicin (DOX) analog, 13-deoxy, 5-iminodoxorubicin (DIDOX),
was synthesized to prevent quinone redox cycling and alcohol metabolite
formation, two prevailing hypotheses of anthracycline cardiotoxicity. The
chronic cardiotoxicity of DOX and DIDOX was compared. Since a recent hypothesis
posits that DOX-induced chronic cardiotoxicity may be mediated by inhibition of
the topoisomer...
Metabolomic profiling to evaluate the efficacy of proxalutamide, a novel androgen receptor antagonist, in prostate cancer cells
Investigational New Drugs - Tập 38 - Trang 1292-1302 - 2020
Proxalutamide is a newly developed androgen receptor (AR) antagonist for the
treatment of castration-resistant prostate cancer (PCa) that has entered phase
III clinical trials. In the present study, we intended to elucidate the
antitumor efficacy of proxalutamide through the metabolomic profiling of PCa
cells. Two AR-positive PCa cell lines and two AR-negative PCa cell lines were
investigated. Cel...
Brigatinib pharmacokinetics in patients with chronic hepatic impairment
Investigational New Drugs - Tập 41 - Trang 402-410 - 2023
Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor approved for the
treatment of ALK-positive non-small cell lung cancer. This open-label,
parallel-group study investigated the effect of chronic hepatic impairment on
the pharmacokinetics (PK) of brigatinib to inform dosing recommendations for
these patients. Participants with hepatic impairment classified according to
Child-Pugh categorie...
A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer
Investigational New Drugs - Tập 40 - Trang 308-313 - 2021
Background. Anlotinib hydrochloride is an oral small molecule inhibitor of
multiple tyrosine kinases, and it has been approved as a third-line therapy for
patients with advanced non-small-cell lung cancer (NSCLC) in China. This
dose-exploration study was designed to investigate the feasibility of anlotinib
in combination with other chemotherapy regimens in patients with nonsquamous
NSCLC. Methods....
Tổng số: 2,526
- 1
- 2
- 3
- 4
- 5
- 6
- 10